Windtree Therapeutics
 | This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these template messages)
|
| Formerly | Discovery Laboratories Inc |
|---|---|
| Company type | Public |
| Nasdaq: WINT | |
| Industry | Healthcare – biotechnology |
| Founded | 1992 |
| Headquarters | , United States |
Key people | John G. Cooper (Chief Executive Officer, President, Chief Financial Officer, and Director) Thomas F. Miller Ph.D. (Chief Accounting Officer) (Dec 31, 2012) |
| Services | Respiratory critical care |
| Revenue | $ 510.00K (Sep 30, 2013) |
Number of employees | 119 (Sep 30, 2013) |
| Website | windtreetx |
Windtree Therapeutics, Inc. (formerly Discovery Laboratories) is an American company which was set up in 1992 and now is based in Warrington, Pennsylvania, developing drug products (pulmonary medicine) for patients with respiratory disease. The company joined an alliance with Laboratorios del Dr. Esteve, S.A.[1] In 2016, Discovery Laboratories changed name to Windtree Therapeutics, Inc.[2]
Products and services[edit]
The major products of the company are Surfaxin (based on its capillary aerosol-generating technology) and Aerosurf. Surfaxin is a synthetic, peptide-containing (KL4) surfactant, similar to pulmonary surfactant, which is naturally in the lung for normal respiratory function. The drug is delivered by its capillary aerosol-generating technology to the lung. Aerosurf is a drug-device combination to prevent respiratory distress syndrome (RDS) in premature infants. In addition, the company also provides Afectair devices (disposable aerosol-conducting airway connectors).[3]
Research and development[edit]
In November 2013, Discovery Laboratories began its phase II clinical program of aerosolized KL4 since U.S. Food and Drug Administration (FDA) had cleared the investigational new drug (IND) application. The phase II consists of two steps to evaluate the safety and tolerability of the drug and determine the optimal dose for premature infants with respiratory distress syndrome (RDS)[4]
In October 2013, Discovery Laboratories received the agreement of updating Surfaxin (lucinactant) Intratracheal Suspension from the U.S. Food and Drug Administration (FDA) to prevent respiratory distress syndrome (RDS) in premature infants.[5]
In September 2012, Discovery Laboratories started the four research projects to explore the KL4 surfactant technology for acute lung injury (ALI). These projects are funded through government-sponsored, biodefense-related initiatives under the Project Bioshield Act of 2004 and the Pandemic and All-Hazards Preparedness Act of 2006.[6]
References[edit]
- ^ "Business Summary".
- ^ source
- ^ "Products: Overview". Reuters. Archived from the original on 2009-04-12.
- ^ "Discovery Labs Receives FDA Clearance of IND to Initiate AEROSURF® Phase 2 Clinical Program" (Press release).
- ^ "Discovery Labs Announces FDA Approval of SURFAXIN® (lucinactant) Updated Product Specifications" (Press release).
- ^ "Discovery Labs Initiates Research Projects with Leading Research Institutions and US Government Agencies to Assess KL(4) Surfactant Utility in Acute Lung Injury" (Press release).